Article
Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 6 Nov 2025
Loosli Tom, Bolton Moore Carolyn, Buzaalirwa Lydia, Byakwaga Helen, Çelikağ İpek, Chimbetete Cleophas, Ebasone Peter Vanes, Giandhari Jennifer, Han Nuri, Huwa Jacqueline, Kasozi Charles, Mafoua Adolphe, Messou Eugène, Minga Albert, Muula Guy, Muyindike Winnie, Ndala Arcel Christ Massamba, Sauermann Mamatha, Semeere Aggrey, Singh Lavanya, Kouyos Roger D, Lessells Richard, Egger Matthias
Abstract excerpt
Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
